Effectiveness of Shallomin syrup on patients affected by COVID-19
Phase 3
- Conditions
- COVID-19.COVID-19U07.1
- Registration Number
- IRCT20200504047295N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
COVID-19 patients who have clinical signs of COVID-19 infection such as fever, cough, sputum production, sore throat.
Patients with the positive CT scan
Patients with the positive RT-qPCR for corona virus 2019
Patients who declare informed consent for enrollment in this study.
Exclusion Criteria
Pregnant women (based on WHO protocol)
Lactating women (based on WHO protocol)
Individuals who exhibit specific allergic reactions to shallomin syrup.
Patients with heart failure, kidney failure, hepatitis, hemophilia, thalassemia or leukemia
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hospitalization duration. Timepoint: About one week after starting the treatment. Method of measurement: Clinical and laboratory questionnaire.;Death in hospital. Timepoint: About one week after starting the treatment. Method of measurement: vital signs.;Blood oxygen saturation. Timepoint: Every day. Method of measurement: Pulse blood oximeter.;Fever. Timepoint: Every day. Method of measurement: Oral thermometer.
- Secondary Outcome Measures
Name Time Method Complete Blood Count (CBC). Timepoint: The first and end of intervention week. Method of measurement: H one devise.;Erythrocyte sedimentation rate (ESR). Timepoint: The first and end of intervention week. Method of measurement: Sediment pipette.